Analysis of whether Mavakatai (Mefanto) can completely cure cardiac hypertrophy and its treatment prospects

Mavacamten is a new type of myosin inhibitor (myosin inhibitor), mainly used to treat hypertrophic cardiomyopathy (HCM), especially hypertrophic obstructive cardiomyopathy (HOCM). Its mechanism of action is to selectively inhibit the interaction between β-myosin and actin in myocardial fibers, thereby reducing excessive contractility and improving ventricular outflow tract obstruction and diastolic dysfunction. This targeting mechanism not only relieves symptoms, but also improves myocardial structure and hemodynamic indicators to a certain extent.

Clinical studies have shown that Mavakatai can significantly improve patients' exercise tolerance, cardiac function indicators and symptom scores. For example, in the EXPLORER-HCM trial, after patients took the drug, the ventricular outflow tract pressure difference decreased, exercise capacity (6 minutes of walking distance) improved, and subjective symptoms such as dyspnea and fatigue were significantly relieved. In addition, some patients' myocardial thickness and fibrosis indicators have also improved under long-term treatment, demonstrating the partial reversibility of pathological changes caused by drugs.

Although Mavaceta has a significant effect in improving symptoms and ventricular structure, it is not yet considered that it can completely cure myocardial hypertrophy Cardiac hypertrophy involves genetic mutations, fibrosis, and changes in cell signaling pathways. Drugs can alleviate pathological contraction and improve function, but they cannot completely reverse genetic abnormalities or eliminate existing myocardial fibrosis. Therefore, Mavaceta is viewed more as a long-term management and symptom control treatment rather than a radical cure.

The emergence of Mavacatel has brought a revolutionary treatment option to patients with hypertrophic cardiomyopathy, and its long-term prospects are relatively optimistic. As more long-term follow-up and real-world data accumulate, it may be possible to optimize the dosage regimen and combine it with other drug use strategies in the future to further improve cardiac function and quality of life. In addition, the development of gene therapy and myocardial regeneration research may be used in combination with Mavaceta in the future to achieve greater breakthroughs in pathological reversal. Overall, Mavaceta is an important drug for the management of cardiac hypertrophy and its application prospects are broad, but its radical cure still requires comprehensive treatment and the support of scientific research progress.

Reference link:https://www.drugs.com